Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
Crossref DOI link: https://doi.org/10.1007/s40261-014-0240-z
Published Online: 2014-12-10
Published Print: 2015-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Aballéa, Samuel
Maman, Khaled
Thokagevistk, Katia
Nazir, Jameel
Odeyemi, Isaac A. O.
Hakimi, Zalmai
Garnham, Andy
Toumi, Mondher
License valid from 2014-12-10